Tatva Chintan Pharma Chem Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9nli176xgf6pgouu6o7200qv.pdf

Key Takeaways


Revenue Performance & Drivers

Chintan Shah: "That is one, if someone can answer that question, because this is what we have been -- see, I told just a couple of questions back that prices are trying to scale up, but not sustain and again fall back. But the good part is, at least, they are not falling down below the current level. So that's a good part."

Dahej Plant & Capacity Expansion


New Business Verticals

Chintan Shah: "It is something very new in terms of technology. And surprisingly, it has been working very consistently up to the pilot, and the samples have been approved, material has been put to use by customers -- number of customers. And things look fine. So now there is no rhyme and reason why we should not go and scale up this opportunity."

Jolva Greenfield Project


Segment Outlook & Growth Levers

Chintan Shah: "The thing, which probably differentiates my views from the rest of the industry is because we had absolutely nearly no presence in this sector, let us say, a year or two years back. So whatever development that we have brought into this segment has come with lot of innovative technologies. So we have kept ourselves largely away from conventional chemistry and focused largely on catalytic or electrolytic chemistries."

Margins & Financial Expectations


Guidance & Commitments

CommitmentSpecificsTimeline
Dahej new block commercial productionCommercial production to beginFirst week of March 2026
Jolva greenfield groundbreakingBreak ground at Jolva, DahejCurrent quarter (Q4 FY26), around mid-February
Jolva plant commissioningCommissioning and commercial useSeptember or October 2027
FY26 revenue growth20% to 30% YoY growth "definitely achievable"FY26
FY27 revenue growthSimilar to FY26, with potential for larger growth if Jolva is commissionedFY27
Overall revenue from existing plantINR850-900 crore at current pricing levelsWithin 2.5 to 3 years
EBITDA margin20% to 22% realistically achievableFY27
SDA segment growth25% to 30% growthOngoing
New intermediates revenueINR200-250 crore from six intermediates (3 agro, 3 pharma)Calendar year 2027
Pharma intermediate revenueINR150 croreCalendar year 2028
Semiconductor full commercializationGradual ramp-up to full commercializationAround 2028
New SDA customer commercial suppliesCommercial supplies to beginAround August 2026
Pharma commercialization consolidationDemand to consolidate after intermittent validation phaseQ2 FY27

Key Metrics

MetricQ3 FY26
Revenue (Pharma & Agro Intermediates and Specialty Chemicals)₹47.1 cr, 45% sequential growth and 86% YoY increase
Revenue (Structured Directing Agents)₹53.4 cr, 10% decline QoQ and 65% YoY growth
SDA 9-month revenue₹150 cr
Overall revenue target₹850 cr to ₹900 cr, achievable in 2.5 to 3 years at current pricing levels
FY26 YoY growth guidance20% to 30%
FY27 YoY growth guidanceSimilar to FY26
EBITDA margin target20% to 22%, realistically achievable; FY27 expected to reach this range
ROCE~7% currently
SDA capacity utilization~50% currently, had been as low as 35%, now roughly 55%
SDA segment growth expectation25% to 30%
Electrolyte Salts revenue contribution expectation7% to 8% of revenue in calendar year 2026, up from ~1% currently
New agro and pharma intermediates revenue target₹200 cr to ₹250 cr in calendar year 2027
New product revenue target₹150 cr in calendar year 2028
Dahej new block capex~₹100 cr (final number pending, roughly ₹102 cr range)
Jolva greenfield phase 1 capex₹265 cr to ₹270 cr (final amount pending)
Jolva plant commissioning timelineSeptember or October 2027
Semiconductor full-scale commercializationExpected around 2028